Vytorin/Zetia Drug Marketing

Result: $41.5 million settlement
Year: 2010

In re Vytorin/Zetia Marketing, Sales Practices & Products Liability Litigation

Lieff Cabraser served on the Executive Committee of Plaintiffs’ Steering Committee in multidistrict litigation arising out of the sale and marketing of Vytorin and Zetia, two cholesterol drugs marketed and sold by Merck/Schering-Plough Pharmaceuticals, a joint venture between Merck & Co., Inc. and Schering-Plough Corp.

Plaintiffs alleged that Vytorin and Zetia were marketed as being more effective than other anti-cholesterol drugs and were sold at higher prices when they were no more effective than less expensive anti-cholesterol drugs.

On February 9, 2010, the Court granted final approval to a $41.5 million settlement for persons and entities which paid for these drugs between November 2002 and the date of final approval of the settlement.

Civil Litigation News